Comparing metabolomic and pathologic biomarkers alone and in combination for discriminating Alzheimer's disease from normal cognitive aging.
about
Genetic studies of quantitative MCI and AD phenotypes in ADNI: Progress, opportunities, and plansUntargeted metabolomic analysis of human plasma indicates differentially affected polyamine and L-arginine metabolism in mild cognitive impairment subjects converting to Alzheimer's diseaseThe Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement.Metabolic profiling of a transgenic Caenorhabditis elegans Alzheimer model.Understanding the cholesterol metabolism-perturbing effects of docosahexaenoic acid by gas chromatography-mass spectrometry targeted metabonomic profiling.Metabolic network failures in Alzheimer's disease: A biochemical road map.Metabolomic Strategies Involving Mass Spectrometry Combined with Liquid and Gas Chromatography.Metabolomic-guided discovery of Alzheimer's disease biomarkers from body fluid.Identification of a plasma signature of psychotic disorder in children and adolescents from the Avon Longitudinal Study of Parents and Children (ALSPAC) cohort.Repeated implantation failure versus repeated implantation success: discrimination at a metabolomic level.Metabolomic profiling of serum in the progression of Alzheimer's disease by capillary electrophoresis-mass spectrometry.Diagnostic Biomarkers of Alzheimer's Disease as Identified in Saliva using 1H NMR-Based Metabolomics.
P2860
Q26801647-DBEB6CEB-8F89-4482-BB7B-48B7C8D56073Q28544957-7AECF4FB-78E1-4412-84DD-551480239198Q31147579-DB7381BE-DFD9-4D3A-9AB6-CC155238B59FQ35573492-11C38C87-9149-4CCF-BBB1-FE0A405C5F24Q38830903-5B601708-7B6A-45B7-8A1D-D0FC8F894BFEQ38877855-354A6DC6-D7AE-4897-8962-EB2FD15BFF57Q38993393-A8EEE01E-8769-45B2-8FE8-E200F188870BQ39181900-EFB3B3E8-0B2F-4E35-86B0-5ACB72AE5520Q42257121-1481609A-F371-4CFC-858D-04B5BABB2AD2Q47832020-242F37B0-FDB2-42A7-A869-02FF2F062A86Q53355934-E99FF91A-87FA-4165-B92F-358C917AD06DQ53388944-C307004F-7D24-4807-9291-96F088053814
P2860
Comparing metabolomic and pathologic biomarkers alone and in combination for discriminating Alzheimer's disease from normal cognitive aging.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 27 June 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Comparing metabolomic and path ...... e from normal cognitive aging.
@en
Comparing metabolomic and path ...... e from normal cognitive aging.
@nl
type
label
Comparing metabolomic and path ...... e from normal cognitive aging.
@en
Comparing metabolomic and path ...... e from normal cognitive aging.
@nl
prefLabel
Comparing metabolomic and path ...... e from normal cognitive aging.
@en
Comparing metabolomic and path ...... e from normal cognitive aging.
@nl
P2093
P2860
P50
P356
P1476
Comparing metabolomic and path ...... e from normal cognitive aging.
@en
P2093
Alison A Motsinger-Reif
Dina H Appleby
Hongjie Zhu
P Murali Doraiswamy
Swati Sharma
Wayne Matson
P2860
P2888
P356
10.1186/2051-5960-1-28
P50
P577
2013-06-27T00:00:00Z